Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.

Full Abstract

BACKGROUND:
To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinases.

METHODS:
Lapatinib was given orally once a day at doses ranging from 1200 to 1800 mg in a phase I study. CT and FDG-PET were performed before treatment, and at 1, 2 and 3 months after the initiation of the treatment and every 2 months thereafter.

RESULTS:
A total of 29 FDG-PET examinations were performed in eight patients with various solid tumors and the metabolic activity in the tumor was evaluated as SUVmax. The best responses, as assessed by CT, were as follows; one partial response, four stable disease and three disease progression. The partial response was observed in a patient with trastuzumab-resistant breast cancer, whose SUVmax was decreased by 60% from baseline. In all of the four patients whose best response was stable disease, the SUVmax was decreased by 6-42% one month after the start of treatment. Prolonged stable disease (10 months) was observed in a patient with colon cancer, whose SUVmax was decreased by 42%. In the patient group with disease progression, SUVmax was increased in two out of three patients.

CONCLUSIONS:
FDG-PET detected decreases in the metabolic activity of the tumors in patients who experienced clinical benefits on treatment with lapatinib. Thus, FDG-PET may be useful for the evaluation of molecular targeted drugs, such as lapatinib.

Learn Faster Today Improve your study skills

Author information

Author/s: Kawada, Kenji (K); Murakami, Koji (K); Sato, Takashi (T); Kojima, Yoshiki (Y); Ebi, Hiromichi (H); Mukai, Hirofumi (H); Tahara, Makoto (M); Shimokata, Kaoru (K); Minami, Hironobu (H);

Affiliation: Department of Oncology/Hematology, National Cancer Center Hospital East, Kashiwa, Japan.

Journal and publication information

Publication Type: Clinical Trial, Phase I; Journal Article

Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol), published in Japan. (Language: eng)

Reference: 2007-Jan; vol 37 (issue 1) : pp 44-8

Dates: Created 2007/02/02; Completed 2007/10/22;

PMID: 17060407, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adult
Aged
Antineoplastic Agents - therapeutic use
Female
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Neoplasms - diagnosis; drug therapy

Positron-Emission Tomography
Prospective Studies
Protein Kinase Inhibitors - therapeutic use
Quinazolines - therapeutic use
Radiopharmaceuticals
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, erbB-2 - antagonists & inhibitors
Tomography, X-Ray Computed
Treatment Outcome

Associated Chemicals: Antineoplastic Agents (0) ; Protein Kinase Inhibitors (0) ; Quinazolines (0) ; Radiopharmaceuticals (0) ; lapatinib (0) ; Fluorodeoxyglucose F18 (63503-12-8) ; Receptor, Epidermal Growth Factor (EC 2.7.1.112) ; Receptor, erbB-2 (EC 2.7.1.112)

These are the highest related articles currently in the database:

See 100+ related articles.